To read the full article, simply click here to claim your deal and get access to all exclusive Business Insider PRIME content.
Frequency Therapeutics - $147 million
Leyla B/ EyeEm/ Getty Images
The biotech company is focused on creating therapies that repair damage caused to the ear by a range of degenerative diseases.
Frequency's initial focus is on sensorineural hearing loss, the most common type of hearing loss, which is caused by damage to the fine hairs in the inner ear that sense sound waves.
In July 2019, Astellas Pharma obtained exclusive rights to develop and commercialize the drug outside of the US, with Frequency receiving $80 million immediately.